# ZymoBiotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zymobiotech

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.zymobiotech.com/
- Total disclosed funding: $2.8M
- Latest round: Series B (May 10, 2026)
- Investors on record: 6

## About

Based in Wuhan, China and founded in 2021, Wuhan Ruijiakang Biotechnology Co., Ltd., trading under the name ZymoBiotech, provides synthetic biology manufacturing and gene editing technology for the renewable energy and biomaterials sectors. The firm established a one-stop data analysis platform “ZymOmics” for Zymomonas mobilis and developed the GW-ICE circular gene editing system to produce compounds from non-food biomass. The company's founder is Professor Shihui Yang. In May 2026, the firm raises a series B funding.

The company works with energy and materials manufacturing enterprises to provide non-food synthetic biofuel and biomaterial products. The core business includes the proprietary ZymOmics platform, which provides services such as gene editing, biological component screening, and strain genotype and phenotype association analysis databases. Additionally, the company designs industrial strains utilizing agricultural straw and waste starch to produce bulk platform compounds such as fuel ethanol, lactic acid, 1,3-propanediol, isobutanol, and 1,4-butanediol.

The company generates revenue by providing ZymOmics synthetic biology platform technology services and directly selling bulk alcohol and acid platform compounds through B2B contracts.

The company plans to use the latest funding to advance from research into large scale production and build industrial capacity for bio based chemical manufacturing.

## Funding rounds

- Series B, May 10, 2026 — Efung Capital, Qingshan Industrial Investment Group
- Series A, Apr 12, 2024 — CDH Investments, Shouyi Technology Innovation Group
- Series A, Aug 14, 2023, $2.8M — Co-Win Ventures, Anhui Huaheng Biotechnology Co., Ltd.

## Investors

- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series A
- Anhui Huaheng Biotechnology Co., Ltd. — Series A
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series A
- Shouyi Technology Innovation Group — Series A
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- Qingshan Industrial Investment Group — Series B